US FDA expands approval for J&J’s drug for rare blood disorder
By Kunal Das and Padmanabhan Ananthan Aug 24 (Reuters) – The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson’s drug to treat a rare blood disorder, the company said on Monday. The approval makes Imaavy the first treatment cleared for warm autoimmune hemolytic anemia, or wAIHA, and covers patients aged 12 and older who are currently or were previously treated with steroids. The life-threatening […]